Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06721507 · ClinicalTrials.gov registry record · Phase 4

2024 Tirzepatide-Bariatric Surgery

A Phase 4 study of Bariatric Surgery and Obesity and Obesity-related Medical Conditions, sponsored by Marlene Starr.

Recruiting
Registry status
Phase 4
Development phase
50
Enrollment target
1
Study location

NCT06721507 is a Phase 4 study of Bariatric Surgery and Obesity and Obesity-related Medical Conditions that is actively recruiting participants, run by Marlene Starr. The registered enrollment target is 50 participants, below the 96-participant average among 15 other Bariatric Surgery trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06721507, a Phase 4 study of Bariatric Surgery and Obesity and Obesity-related Medical Conditions, is actively recruiting participants, sponsored by Marlene Starr.

RECRUITING
Registry status
Phase 4
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This clinical trial will test whether preoperative tirzepatide treatment improves outcomes after bariatric surgery. The outcome of this study could impact therapeutic guidelines for the multimodal treatment of obesity. The major objectives are: 1. To evaluate whether pre-operative tirzepatide treatment reduces tissue and circulating inflammatory markers at the time of surgery. 2. To establish the relationship of these changes with postoperative improvements in weight loss, metabolic and inflammatory profiles, comorbidity resolution (glycemic control, blood pressure, lipid profile), and 30-day surgical complications. Researchers will compare data from patients taking tirzepatide to data from patients not taking tirzepatide before their planned bariatric surgery to see if tirzepatide reduces inflammation and improves health outcomes after bariatric surgery. Participants will: Take or not take tirzepatide, depending on what study group they are in, once a week for 3 months. Visit the endocrine clinic once a month for 3 months to be prescribed the drug and for checkups regarding side effects due to the drug. Keep a diary to document taking the drug and any side effects. Continue with their planned bariatric surgery and post-surgery follow-ups according to their healthcare provider.

Interventions

  • BEHAVIORAL Standard of Care
  • DRUG tirzepatide

Study Locations (1)

Kentucky

  • University of Kentucky - Lexington

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-03-27
Est. Completion 2026-12-31
Phase Phase 4

Sponsor

Marlene Starr

1 total trials

What the Registry Record Tells You About NCT06721507

The ClinicalTrials.gov registry entry for NCT06721507 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 15 other Bariatric Surgery trials with a reported enrollment target (48% lower). The listed sponsor is Marlene Starr, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Bariatric Surgery appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.

NCT06721507 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.

Frequently Asked Questions

What is clinical trial NCT06721507 about?

NCT06721507 is a clinical study titled "2024 Tirzepatide-Bariatric Surgery". This clinical trial will test whether preoperative tirzepatide treatment improves outcomes after bariatric surgery. The outcome of this study could impact therapeutic guidelines for the multimodal treatment of obesity. The major objectives are: 1. To evaluate whether pre-operative tirzepatide trea...

What is the current status of trial NCT06721507?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2025-03-27. Estimated completion is 2026-12-31.

What conditions does trial NCT06721507 study?

This clinical trial studies the following conditions: Bariatric Surgery, Obesity and Obesity-related Medical Conditions.

What interventions are being tested in trial NCT06721507?

The interventions under investigation include: Standard of Care (BEHAVIORAL), tirzepatide (DRUG).

Who is sponsoring clinical trial NCT06721507?

This trial is sponsored by Marlene Starr, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06721507 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bariatric Surgery

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.